⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

July 4, 2024BMC Infectious DiseasesOpen Access

Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals, or no treatment: a retrospective cohort study

Myriam Drysdale Holly Tibble Vishal Patel Daniel C. Gibbons Emily J. Lloyd William A. Kerr C. M. Macdonald Helen J. Birch Aziz Sheikh

View Full Paper

Ask AI

Bookmark

Share

Abstract

The clinical benefit of coronavirus disease 2019 (COVID-19) treatments against new circulating variants remains unclear. We sought to describe characteristics and clinical outcomes of highest risk patients with COVID-19 receiving early COVID-19 treatments in Scotland.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Drysdale et al. (2024) studied this question.

synapsesocial.com/papers/68e615d9b6db6435875a8631 https://doi.org/10.1186/s12879-024-09576-7

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals or no treatment in England: a retrospective cohort study2024 · 9 citations
2Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England2024 · 15 citations
3Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records2024 · 4 citations
4Real-world severe COVID-19 outcomes associated with use of antivirals and neutralising monoclonal antibodies in Scotland2024 · 6 citations
5Comparative effectiveness of sotrovimab versus no treatment in non-hospitalised high-risk COVID-19 patients in north west London: a retrospective cohort study2024 · 3 citations